The song is definately coming to an end. Quick, everybody look for a chair!
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
-
Make it like cafepharma, but for different industries. Learn more about CompanyUnderground
Anonymous
Guest
Anonymous
Guest
The cuts will be swift and massive. Brand teams will merge. Functional teams will be cut. Sales force will have the deepest cuts.
Management will be streamlined.
Expect bad bonus payouts.
Management will be streamlined.
Expect bad bonus payouts.
Anonymous
Guest
Anonymous
Guest
"..failed to save more lives than a placebo..."
“This is harsh,” Atsushi Seki, an equities analyst at Barclays Plc in Tokyo, said by telephone today. “I can’t see Eisai’s next step to bring growth. It has debt, it’s hard to see growth in its pipeline and its cash will be tight.”
Lusedra is just the beginning, more layoffs seem imminent. Polish those resumes.
“This is harsh,” Atsushi Seki, an equities analyst at Barclays Plc in Tokyo, said by telephone today. “I can’t see Eisai’s next step to bring growth. It has debt, it’s hard to see growth in its pipeline and its cash will be tight.”
Lusedra is just the beginning, more layoffs seem imminent. Polish those resumes.
Anonymous
Guest
Anonymous
Guest
This was supposed to be a billion dollar drug. I know it was being banked on big time. This one might be the curtain closer for a whole lot of jobs here in the US.
Anonymous
Guest
Anonymous
Guest
Anonymous
Guest
No reason for Woodcliff Lake to exist as it does today.
Give AcipHex to J&J to manage.
Give Aricept 23 to Pfizer.
Aloxi is nothing special. Fragmin -- joke. Lusedra -- dead. Banzel -- doesn't need a team. Lymphoma -- outsource. Eribulin -- needs a small team and small field force.
No need for a managed markets team at all.
What am I missing?
Give AcipHex to J&J to manage.
Give Aricept 23 to Pfizer.
Aloxi is nothing special. Fragmin -- joke. Lusedra -- dead. Banzel -- doesn't need a team. Lymphoma -- outsource. Eribulin -- needs a small team and small field force.
No need for a managed markets team at all.
What am I missing?
Anonymous
Guest
Anonymous
Guest
No reason for Woodcliff Lake to exist as it does today.
Give AcipHex to J&J to manage.
Give Aricept 23 to Pfizer.
Aloxi is nothing special. Fragmin -- joke. Lusedra -- dead. Banzel -- doesn't need a team. Lymphoma -- outsource. Eribulin -- needs a small team and small field force.
No need for a managed markets team at all.
What am I missing?
Dacogen !!
Anonymous
Guest
Anonymous
Guest
Oh yeah, Dacogen.
hmm. Put that with Eribulin and call it a day.
hmm. Put that with Eribulin and call it a day.
Anonymous
Guest
Anonymous
Guest
Oh yeah, Dacogen.
hmm. Put that with Eribulin and call it a day.
All kidding aside, eritorin not moving forward is really bad news for eisai. no way to put a positive spin on it. company will no doubt have position cuts across the board, including sales and home office.
Anonymous
Guest
Anonymous
Guest
All kidding aside, eritorin not moving forward is really bad news for eisai. no way to put a positive spin on it. company will no doubt have position cuts across the board, including sales and home office.
True that.
Anonymous
Guest
Anonymous
Guest
http://www.bloomberg.com/news/2011-...-to-save-more-lives-in-final-stage-study.html
Eisai's Sepsis Drug Eritoran Fails to Save More Lives in Final-Stage Study
By Kanoko Matsuyama - Jan 25, 2011 2:04 AM ET
inShare
3More Print Email
Eisai Co. said its experimental drug to treat severe sepsis failed to save more lives than a placebo in a final-stage study.
The company won’t seek regulatory approval for eritoran in the U.S., Europe and Japan by March 31 this year as previously planned, Tokyo-based Eisai said in a statement today. Eisai will continue analyzing the trial data and determine its next course of action, it said.
Eritoran was on course to be the first new treatment in a decade for the disease caused by bacterial infection that causes the immune system to attack the body, killing one in three patients in the U.S. The trial result is a setback for Eisai, which needs new medicines to cope with generic-drug competition after its Aricept, the world’s best-selling Alzheimer’s disease treatment, lost patent protection in the U.S. in November.
Many previous trials of potential drugs have failed to improve patients’ outcome, said Mark Tidswell, interim chief of the critical care unit at Baystate Medical Center in Springfield, Massachusetts.
“Severe sepsis remains an unmet need with few options,” Tidswell, who was part of an earlier eritoran trial, said in an e-mail before Eisai’s announcement.
Eisai rose 0.2 percent to 2,954 yen at the 3 p.m. close of trading in Tokyo, before the company’s announcement. The Nikkei 225 Stock Average advanced 1.2 percent.
Eisai's Sepsis Drug Eritoran Fails to Save More Lives in Final-Stage Study
By Kanoko Matsuyama - Jan 25, 2011 2:04 AM ET
inShare
3More Print Email
Eisai Co. said its experimental drug to treat severe sepsis failed to save more lives than a placebo in a final-stage study.
The company won’t seek regulatory approval for eritoran in the U.S., Europe and Japan by March 31 this year as previously planned, Tokyo-based Eisai said in a statement today. Eisai will continue analyzing the trial data and determine its next course of action, it said.
Eritoran was on course to be the first new treatment in a decade for the disease caused by bacterial infection that causes the immune system to attack the body, killing one in three patients in the U.S. The trial result is a setback for Eisai, which needs new medicines to cope with generic-drug competition after its Aricept, the world’s best-selling Alzheimer’s disease treatment, lost patent protection in the U.S. in November.
Many previous trials of potential drugs have failed to improve patients’ outcome, said Mark Tidswell, interim chief of the critical care unit at Baystate Medical Center in Springfield, Massachusetts.
“Severe sepsis remains an unmet need with few options,” Tidswell, who was part of an earlier eritoran trial, said in an e-mail before Eisai’s announcement.
Eisai rose 0.2 percent to 2,954 yen at the 3 p.m. close of trading in Tokyo, before the company’s announcement. The Nikkei 225 Stock Average advanced 1.2 percent.
Anonymous
Guest
Anonymous
Guest
The news is here. The question now is---how many field jobs will go? Thoughts?
40%.
Anonymous
Guest
Anonymous
Guest
Given the high-risk nature of eritoran, most analysts had already heavily risk-adjusted their forecasts for the drug, which before Tuesday sat at $477m by 2016. Decent revenues but not fully reflective of the potential market size - Eisai had estimated peak sales of $1bn while one Barclays analyst predicted sales of over $2bn in 2021 would be possible.
Assuming further trials are required, a minimum two-year delay to launch until 2014 can be expected which would significantly reduce current estimates. With a potential value of $1.33bn, according to 'EvaluatePharmas NPV Analyzer, representing up to 13% of Eisai's market capitalization, the stock could be in for a significant fall Wednesday. The news broke after the Tokyo stock exchange closed.
Either way the potential loss of eritoran is tough to take as Eisai grapples with the recent loss of US patent protection for its biggest drug, Aricept, the gold standard therapy for Alzheimer's disease which sold nearly $4bn last year – global sales are expected to halve by 2014.
Assuming further trials are required, a minimum two-year delay to launch until 2014 can be expected which would significantly reduce current estimates. With a potential value of $1.33bn, according to 'EvaluatePharmas NPV Analyzer, representing up to 13% of Eisai's market capitalization, the stock could be in for a significant fall Wednesday. The news broke after the Tokyo stock exchange closed.
Either way the potential loss of eritoran is tough to take as Eisai grapples with the recent loss of US patent protection for its biggest drug, Aricept, the gold standard therapy for Alzheimer's disease which sold nearly $4bn last year – global sales are expected to halve by 2014.
Anonymous
Guest
Anonymous
Guest
There goes probably 50% of the sales force! Doesn't matter what team.
If sales are reduced by 50% we will be too!
Face it, the company we once loved is a sinking ship and has been for several years.
And this, all due to "senior leadership" and their wonderful decisions! Do you think any of them will be worrying about layoffs?
If sales are reduced by 50% we will be too!
Face it, the company we once loved is a sinking ship and has been for several years.
And this, all due to "senior leadership" and their wonderful decisions! Do you think any of them will be worrying about layoffs?
Anonymous
Guest
Anonymous
Guest
HELL NO they won't. They will still be sitting in their cushy offices in WCL collecting their fat salaries as the ship goes down. And probably still blaming the sales force for lack of scripts and drive.
Anonymous
Guest
Anonymous
Guest
HELL NO they won't. They will still be sitting in their cushy offices in WCL collecting their fat salaries as the ship goes down. And probably still blaming the sales force for lack of scripts and drive.
Going out on a limb here but I'm guessing LC will be replaced. Japan will replace LC with a Japanese CEO.
Anonymous
Guest
Anonymous
Guest
Going out on a limb here but I'm guessing LC will be replaced. Japan will replace LC with a Japanese CEO.
Now that would be a brilliant solution.
Anonymous
Guest
Anonymous
Guest
Given the high-risk nature of eritoran, most analysts had already heavily risk-adjusted their forecasts for the drug, which before Tuesday sat at $477m by 2016. Decent revenues but not fully reflective of the potential market size - Eisai had estimated peak sales of $1bn while one Barclays analyst predicted sales of over $2bn in 2021 would be possible.
Assuming further trials are required, a minimum two-year delay to launch until 2014 can be expected which would significantly reduce current estimates. With a potential value of $1.33bn, according to 'EvaluatePharmas NPV Analyzer, representing up to 13% of Eisai's market capitalization, the stock could be in for a significant fall Wednesday. The news broke after the Tokyo stock exchange closed.
Either way the potential loss of eritoran is tough to take as Eisai grapples with the recent loss of US patent protection for its biggest drug, Aricept, the gold standard therapy for Alzheimer's disease which sold nearly $4bn last year – global sales are expected to halve by 2014.
Oh my, we are about to get cut.
Anonymous
Guest
Anonymous
Guest
Oh my, we are about to get cut.
Ya think? Suggest you don't miss the all employee meeting on Feb 4.
Anonymous
Guest
Anonymous
Guest
The news is here. The question now is---how many field jobs will go? Thoughts?
Here is a thought-- let's just say you were working for company A which made typewriters. Well a revolutionary new technology came out called the COMPUTER. How long do you think you would be staying at company A?
Just a thought